赵 兵,金 永,李再芹.吉西他滨或卡培他滨联合放疗治疗局部晚期胰腺癌的临床研究[J].肿瘤学杂志,2015,21(7):591-595. |
吉西他滨或卡培他滨联合放疗治疗局部晚期胰腺癌的临床研究 |
Clinical Research of Gemcitabine or Capecitabine Combined with Radiotherapy in the Treatment of Locally Advanced Pancreatic Cancer |
投稿时间:2014-08-15 |
DOI:10.11735/j.issn.1671-170X.2015.07.B013 |
|
|
中文关键词: 胰腺肿瘤 同步放化疗 吉西他滨 卡培他滨 |
英文关键词:pancreatic neoplasms concurrent chemoradiotherapy gemcitabine capecitabine |
基金项目: |
|
摘要点击次数: 1942 |
全文下载次数: 2185 |
中文摘要: |
摘 要:[目的] 探讨吉西他滨或卡培他滨联合放疗治疗局部晚期胰腺癌的疗效和安全性。[方法] 34例不可手术切除的局部晚期胰腺癌患者,分为吉西他滨联合放疗组(A组,17例)和卡培他滨联合放疗组(B组,17例)。观察两组患者的有效率、不良反应及生存情况。[结果] A组与B组总有效率分别为70.6% vs 41.2%,1年生存率58. 8% vs 35.3%,2年生存率29.4% vs 17.6%,1年局部控制率52.9% vs 35.3%,2年局控率23.5% vs 11.8%,均显示出A组有较好的生存和局部控制优势,但两组差异无统计学意义(P>0.05)。A组血液学不良反应发生率较B组高,而B组消化道不良反应发生率较A组高,多为Ⅰ/Ⅱ级,患者可耐受,两组不良反应差异无统计学意义(P>0.05)。[结论] 吉西他滨联合外放疗治疗局部晚期胰腺癌有一定的疗效优势。 |
英文摘要: |
Abstract:[Purpose] To investigate the efficacy and safety of gemcitabine or capecitabine combination with radiotherapy in the treatment of locally advanced pancreatic cancer. [Methods] Thirty-four cases with locally advanced unresectable pancreatic cancer were divided into gemcitabine combined with radiotherapy group (group A,17 cases)and capecitabine combined with radiotherapy group(group B,17 cases). Response rate,toxicities and survival of the two groups were analyzed.[Results] The response rate of group A and group B was 70.6% vs 41.2%;1-year survival rate,58.8% vs 35.3%;2-year survival rate,29.4% vs 17.6%;1-year local control rate,52.9% vs 35.3%;2- year local control rate,23.5% vs 11.8%. Group A had superior survival and local control advantages compared with group B,but no significant difference was found between the two groups(P>0.05). The incidence of hematologic toxicities in group A was higher than that in group B,while gastrointestinal toxicities in group B was higher than that in group A. And these toxicities in the two groups were mostly grade Ⅰ/Ⅱ and tolerable,and no significant difference was found(P>0.05). [Conclusion] Gemcitabine combined with radiotherapy seems to have certain efficacy advantage in the treatment of locally advanced pancreatic cancer patients. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |